Latest Insider Transactions at Genelux Corp (GNLX)
This section provides a real-time view of insider transactions for Genelux Corp (GNLX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GENELUX CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GENELUX CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 01
2025
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+12.35%
|
-
|
|
Aug 27
2025
|
Joseph Cappello Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
107,500
+40.22%
|
-
|
|
Aug 27
2025
|
James L Tyree Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,283
+24.66%
|
-
|
|
Aug 27
2025
|
Mary Mirabelli Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,283
+23.32%
|
-
|
|
Aug 27
2025
|
Tony Yu SVP, Clinical Development |
BUY
Grant, award, or other acquisition
|
Direct |
101,480
+40.35%
|
-
|
|
Aug 27
2025
|
John W Smither Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,283
+22.91%
|
-
|
|
Aug 27
2025
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
26,230
+30.07%
|
-
|
|
Aug 27
2025
|
Thomas Zindrick President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
361,200
+39.46%
|
-
|
|
Aug 27
2025
|
John Thomas Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,283
+4.24%
|
-
|
|
Jun 06
2025
|
John Thomas Director |
SELL
Bona fide gift
|
Direct |
25,000
-4.95%
|
-
|
|
May 12
2025
|
Ralph Smalling Head of Regulatory |
SELL
Open market or private sale
|
Direct |
1,259
-3.5%
|
$2,518
$2.92 P/Share
|
|
May 12
2025
|
Joseph Cappello Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
4,737
-8.31%
|
$9,474
$2.92 P/Share
|
|
May 12
2025
|
Tony Yu SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
5,579
-10.48%
|
$11,158
$2.92 P/Share
|
|
May 12
2025
|
Thomas Zindrick President and CEO |
SELL
Open market or private sale
|
Direct |
10,764
-5.32%
|
$21,528
$2.92 P/Share
|
|
May 12
2025
|
Sean Ryder General Counsel |
SELL
Open market or private sale
|
Direct |
4,475
-8.59%
|
$8,950
$2.92 P/Share
|
|
Mar 14
2025
|
Sean Ryder General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
10,708
+17.05%
|
-
|
|
Mar 14
2025
|
Tony Yu SVP, Clinical Development |
BUY
Grant, award, or other acquisition
|
Direct |
13,350
+20.05%
|
-
|
|
Mar 14
2025
|
Joseph Cappello Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,350
+18.98%
|
-
|
|
Mar 14
2025
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
4,172
+10.38%
|
-
|
|
Mar 14
2025
|
Thomas Zindrick President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
30,339
+13.05%
|
-
|
|
Dec 30
2024
|
James L Tyree Director |
SELL
Open market or private sale
|
Direct |
3,460
-7.03%
|
$6,920
$2.46 P/Share
|
|
Dec 18
2024
|
Lourie S. Zak Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,650
+33.56%
|
-
|
|
Dec 18
2024
|
Joseph Cappello Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,000
+39.92%
|
-
|
|
Dec 18
2024
|
Tony Yu SVP, Clinical Development |
BUY
Grant, award, or other acquisition
|
Direct |
29,000
+42.11%
|
-
|
|
Dec 18
2024
|
Sean Ryder General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+34.71%
|
-
|
|
Dec 18
2024
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
15,525
+32.77%
|
-
|
|
Dec 18
2024
|
Thomas Zindrick President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
134,500
+43.9%
|
-
|
|
Dec 16
2024
|
Joseph Cappello Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
6,300
-30.07%
|
$12,600
$2.34 P/Share
|
|
Dec 16
2024
|
Ralph Smalling Head of Regulatory |
SELL
Open market or private sale
|
Direct |
2,510
-13.33%
|
$5,020
$2.34 P/Share
|
|
Dec 16
2024
|
Lourie S. Zak Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,103
-4.9%
|
$4,206
$2.34 P/Share
|
|
Dec 16
2024
|
Thomas Zindrick President and CEO |
SELL
Open market or private sale
|
Direct |
14,315
-27.7%
|
$28,630
$2.34 P/Share
|
|
Sep 13
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
33,080
-5.23%
|
$66,160
$2.57 P/Share
|
|
Sep 12
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
31,777
-4.78%
|
$63,554
$2.73 P/Share
|
|
Sep 11
2024
|
James L Tyree Director |
SELL
Open market or private sale
|
Direct |
1,730
-3.51%
|
$3,460
$2.6 P/Share
|
|
Sep 11
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
31,376
-4.51%
|
$62,752
$2.62 P/Share
|
|
Sep 10
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
20,384
-2.85%
|
$40,768
$2.51 P/Share
|
|
Sep 09
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
23,383
-3.16%
|
$46,766
$2.7 P/Share
|
|
Sep 03
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
42,818
-5.47%
|
$85,636
$2.09 P/Share
|
|
Aug 30
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
142,589
-15.41%
|
$285,178
$2.17 P/Share
|
|
Aug 29
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
107,045
-10.37%
|
$107,045
$1.98 P/Share
|
|
Aug 28
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
15,918
-1.52%
|
$31,836
$2.05 P/Share
|
|
Aug 27
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
51,630
-4.69%
|
$103,260
$2.11 P/Share
|
|
Aug 23
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
40,000
-3.51%
|
$80,000
$2.29 P/Share
|
|
Aug 01
2024
|
John W Smither Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,541
+42.86%
|
-
|
|
Aug 01
2024
|
John Thomas Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,541
+7.25%
|
-
|
|
Aug 01
2024
|
Mary Mirabelli Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,541
+43.19%
|
-
|
|
Aug 01
2024
|
James L Tyree Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,541
+44.53%
|
-
|
|
Jun 24
2024
|
Caroline Jewett Head of Quality |
SELL
Open market or private sale
|
Direct |
4,961
-23.47%
|
$9,922
$2.12 P/Share
|
|
Jun 24
2024
|
Sean Ryder General Counsel |
SELL
Open market or private sale
|
Direct |
5,496
-22.09%
|
$10,992
$2.12 P/Share
|
|
Jun 24
2024
|
Tony Yu SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
6,849
-38.66%
|
$13,698
$2.12 P/Share
|